Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly life-threatening disease characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) leading to renal and other end-organ damage. We originally conducted two phase 2 studies (26 weeks and 1 year) evaluating eculiz...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Kidney Int
Main Authors: Licht, Christoph, Greenbaum, Larry A, Muus, Petra, Babu, Sunil, Bedrosian, Camille L, Cohen, David J, Delmas, Yahsou, Douglas, Kenneth, Furman, Richard R, Gaber, Osama A, Goodship, Timothy, Herthelius, Maria, Hourmant, Maryvonne, Legendre, Christophe M, Remuzzi, Giuseppe, Sheerin, Neil, Trivelli, Antonella, Loirat, Chantal
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Clinical Trial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4424817/
https://ncbi.nlm.nih.gov/pubmed/25651368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ki.2014.423
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados